文献检索文档翻译深度研究

邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

不再提醒

Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management.

作者信息

Khurana Arushi, Rosenthal Allison C, Mohty Razan, Gaddam Mamatha, Bansal Radhika, Hathcock Matthew A, Nedved Adrienne N, Durani Urshila, Iqbal Madiha, Wang Yucai, Paludo Jonas, Villasboas J C, Dingli David, Kourelis Taxiarchis, Leung Nelson, Alkhateeb Hassan, Ruff Michael W, Gallo de Moraes Alice, Vergidis Paschalis, Herrmann Joerg, Kenderian Saad S, Bennani N Nora, Johnston Patrick B, Ansell Stephen M, Lin Yi

机构信息

Division of Hematology Mayo Clinic, Rochester, MN, USA.

Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA.

出版信息

Blood Cancer J. 2024 Aug 12;14(1):136. doi: 10.1038/s41408-024-01119-2.

DOI:10.1038/s41408-024-01119-2

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11319601/

Abstract

摘要

相似文献

[1]

Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management.

Blood Cancer J. 2024-8-12

[2]

Chimeric antigen receptor T cell immunotherapy‑associated hemophagocytic lymphohistiocytosis: Pathogenesis, clinical manifestation, diagnosis and management compared with cytokine release syndrome (Review).

Mol Med Rep. 2025-8

[3]

Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.

Leuk Lymphoma. 2021-7

[4]

[The diagnosis and treatment of chimeric antigen receptor T-cell associated hemophagocytic lymphohistiocytosis].

Zhonghua Nei Ke Za Zhi. 2025-1-1

[5]

Hemophagocytic lymphohistiocytosis in a patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.

Immunotherapy. 2024

[6]

Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy.

Br J Haematol. 2019-10

[7]

Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy.

Br J Haematol. 2021-8

[8]

Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies.

Int Immunopharmacol. 2020-12

[9]

Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).

Hematol Oncol Clin North Am. 2025-6

[10]

Very unusual extremely high ferritin with cytokine release syndrome in a patient with hematological malignancy after experimental chimeric antigen receptor (CAR)-T-Cell therapy.

Clin Chim Acta. 2024-6-1

引用本文的文献

[1]

Venous Thromboembolic Events in Cancer Immunotherapy: A Narrative Review.

J Clin Med. 2025-7-11

[2]

[Management of side effects of CAR T cells].

Inn Med (Heidelb). 2025-7-8

[3]

Chimeric antigen receptor T cell immunotherapy‑associated hemophagocytic lymphohistiocytosis: Pathogenesis, clinical manifestation, diagnosis and management compared with cytokine release syndrome (Review).

Mol Med Rep. 2025-8

[4]

T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.

Cancers (Basel). 2025-4-30

[5]

Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).

Hematol Oncol Clin North Am. 2025-6

本文引用的文献

[1]

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.

Transplant Cell Ther. 2023-7

[2]

Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).

J Immunother Cancer. 2022-1

[3]

Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.

Blood. 2021-12-16

[4]

Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy.

Br J Haematol. 2021-8

[5]

Novel Use of Extracorporeal Blood Purification for Treatment of Severe, Refractory Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy-A Case Report.

Crit Care Explor. 2021-6-29

[6]

Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?

J Immunother Cancer. 2020-5

[7]

Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP).

Front Immunol. 2020-3-31

[8]

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.

J Clin Oncol. 2020-6-10

[9]

Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy.

Br J Haematol. 2019-10

[10]

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.

Blood. 2019-4-16

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

推荐工具

医学文档翻译智能文献检索